New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
09:25 EDTACT, ACT, ACT, VRX, VRX, VRX, SGEN, SGEN, SGEN, REGN, REGN, REGN, MNK, MNK, MNK, INCY, INCY, INCY, GILD, GILD, GILD, CELG, CELG, CELG, BIIB, BIIB, BIIB, XLRN, XLRN, XLRNPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
News For ACT;BIIB;CELG;GILD;INCY;MNK;REGN;SGEN;VRX;XLRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 9, 2015
11:39 EDTACT, VRXPershing Square, Valeant, Allergan drop lawsuit over buyout
Subscribe for More Information
09:25 EDTBIIBPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
07:27 EDTBIIBBiogen PML death case previously reported, says Deutsche Bank
Subscribe for More Information
07:23 EDTBIIBDoctors report case of fatal PML in patient treated with Tecfidera to NEJM
Subscribe for More Information
06:12 EDTGILDSovaldi prices causes Medicaid spending for hepatitis C drugs to soar, WSJ says
Subscribe for More Information
April 8, 2015
12:17 EDTVRXOn The Fly: Midday Wrap
Subscribe for More Information
09:16 EDTACTActavis COPD drug Daliresp gets Paragraph 4 challenge
Subscribe for More Information
08:56 EDTMNKPerrigo's ANDA for equivalent of Mallinckrodt's Exalgo approved by FDA
Subscribe for More Information
08:05 EDTACTActavis price target raised to $348 from $328 at Leerink
Subscribe for More Information
08:04 EDTACTActavis potential acquisition Rhythm initiates Phase 2b study of relamorelin
Subscribe for More Information
07:34 EDTACTActavis initiates Phase 2b clinical trial of relamorelin
Subscribe for More Information
07:24 EDTBIIBNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
April 7, 2015
17:58 EDTGILDGilead submits NDA for investigational combination for treatment of HIV-1
Subscribe for More Information
16:00 EDTGILDOptions Update; April 7, 2015
Subscribe for More Information
07:31 EDTBIIBBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information
07:24 EDTCELGCelgene Otezla has growing opportunity, says Bernstein
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.
07:14 EDTBIIBEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
April 6, 2015
07:36 EDTGILDGilead Q1 HCV revenue poised to beat expectations, says RBC Capital
After analyzing weekly prescription data, RBC Capital believes that Gilead's weekly hepatitis C prescriptions are tracking towards $3.5B-$3.6B of revenue from hepatitis C drugs for Q1, versus the consensus outlook of about $2.6B. The firm keeps an Outperform rating on Gilead.
07:04 EDTXLRNAcceleron names Francois Nader as chairman
Subscribe for More Information
April 5, 2015
14:43 EDTACT, GILDActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use